The Effects of Rosiglitazone, Metformin, and Estradiol-Cyproterone Acetate on Lean Patients With Polycystic Ovary Syndrome


ÇETİNKALP Ş. , KARADENİZ M. , ERDOĞAN M. , ÖZGEN A. G. , SAYGILI L. F. , YILMAZ C.

ENDOCRINOLOGIST, vol.19, no.3, pp.94-97, 2009 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 3
  • Publication Date: 2009
  • Doi Number: 10.1097/ten.0b013e3181a58772
  • Title of Journal : ENDOCRINOLOGIST
  • Page Numbers: pp.94-97
  • Keywords: polycystic ovary syndrome, dyslipidemia, rosiglitazone, metformin, estradiol-cyproterone acetate, PLASMINOGEN-ACTIVATOR SYSTEM, INSULIN-RESISTANCE, DEHYDROEPIANDROSTERONE-SULFATE, CARDIOVASCULAR-DISEASE, HYPERANDROGENIC WOMEN, ORAL-CONTRACEPTIVES, OBESE WOMEN, SECRETION, HYPERINSULINEMIA, TESTOSTERONE

Abstract

Background: Polycystic ovary syndrome (PCOS) is characterized by anovulation, infertility, and hyperandrogenism. The present study aims to compare the clinical, biochemical, and hormonal changes in PCOS patients taking estradiol-cyproterone acetate (ECA), metformin (MET), and rosiglitazone (ROSI).